David H. Donabedian

Serial founder and operator in early‑stage biotech: Donabedian has repeatedly been a founding or start‑up CEO across multiple Longwood‑founded companies (Newleos, Solu, DEM Bio, ImmuneID, Axial) and has led those companies through platform development, clinical advancement and financing events. longwoodfund+4

Experienced venture and deal strategist: He has held venture and BD leadership roles in industry and at Longwood Fund, combining prior corporate BD/venture experience (AbbVie, GSK, Surface Logix) with operating partner work to form and scale new companies. longwoodfund

Platform‑driven scientific focus spanning CNS and immuno‑oncology: Across companies he has advanced platform approaches—gut‑targeted 'omics' therapeutics for CNS disorders (Axial), macrophage screening platforms for immuno‑oncology (DEM Bio), and bifunctional CyTaC molecules for targeting extracellular antigens (Solu). nature+2

Proven track record raising institutional capital and advancing programs into the clinic: As founding CEO or leader he has been involved in multiple major financings (e.g., DEM Bio $70M, Solu $31M seed, ImmuneID $50M Series A, Newleos Series A ~$93.5M) and clinical advancement of assets. biospace+4